Home › Acute Myeloid Leukemia › Texas › Dallas
Acute Myeloid Leukemia clinical trials in Dallas, TX
21 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Baylor University Medical Center, Dallas
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
RecruitingPhase 1
- Children's Medical Center Dallas /ID# 275930, Dallas
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RecruitingPhase 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- Baylor Scott & White Health, Dallas
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
RecruitingPhase 3
- US-Dallas TX-SOUTHWESTERN, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Harold C. Simmons Comprehensive Cancer Center, Dallas
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- Texas Oncology-Presbyterian Cancer Center, Dallas
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RecruitingPhase 1
- UT Southwestern/Simmons Cancer Center, Dallas
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RecruitingPhase 3
- Baylor Charles A. Sammons Cancer Center, Dallas
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
RecruitingPhase 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
RecruitingPhase 2
- UT Southwestern Medical Center at Dallas, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Baylor University Medical Center, Dallas
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RecruitingPhase 1
- UT Southwestern Medical Center, Dallas
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- UT Southwestern - Simmons Cancer Center, Dallas
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
RecruitingPhase 1
- University of Texas Southwestern Medical Center, Dallas
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA30 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Metastatic Cancer42 studies
- Heart Failure42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity30 studies
- Ovarian Cancer28 studies
- Bladder Cancer27 studies
- Lung Cancer27 studies
- Endometrial Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.